Cargando…
Repurposed agents in the Alzheimer’s disease drug development pipeline
BACKGROUND: Treatments are needed to address the growing prevalence of Alzheimer’s disease (AD). Clinical trials have failed to produce any AD drugs for Food and Drug Administration (FDA) approval since 2003, and the pharmaceutical development process is both time-consuming and costly. Drug repurpos...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433208/ https://www.ncbi.nlm.nih.gov/pubmed/32807237 http://dx.doi.org/10.1186/s13195-020-00662-x |